LivaNova (NSDQ:LIVN) said today that it agreed to a deal for ImThera Medical and its implantable sleep apnea treatment worth $225 million. San Diego-based ImThera’s flagship product is the Aura6000, an implanted hypoglossal nerve stimulator that won FDA investigational device exemption in November 2014 for a pivotal trial. The device uses a pair of implanted components, one near the […]
ImThera Medical has opened for a $10 million equity financing round, according to an SEC filing posted last Friday. The company’s flagship product is the Aura6000, an implanted hypoglossal nerve stimulator for sleep apnea that won FDA investigational device exemption in November 2014. ImThera Medical has already raised $2.7 million from 29 investors, according to the SEC filing from […]
ImThera Medical said the 1st 2 U.S. patients in a clinical study of its Aura6000 sleep apnea therapy were successfully implanted with the device. The surgeries were performed by Dr. Sam Mickelson of Advanced Sleep Centers in Atlanta, Ga.
ImThera Medical said the FDA approved its investigational device exemption application to initiate a clinical study for its Aura6000 System for obstructive sleep apnea.
NuVasive (NSDQ:NUVA) closed its $80 million pickup of Impulse Monitoring Inc. last week, according to a filing with the federal Securities & Exchange Commission.
The deal, which closed Oct. 7, saw IMI’s shareholders receive nearly $40.5 million in cash and more than 2.3 million shares of NuVasive common stock with an aggregate value of about $40.5 million (per NUVA’s Oct. 6 closing share price of $17.32).
ImThera Medical Inc. said its tongue stimulation device for sleep apnea can improve patients’ snooze time.
The San Diego-based device maker concluded a European pilot study of its aura6000, an implanted neurostimulation device for treating obstructive sleep apnea (OSA) that delivers electrical pulses to the tongue during sleep.
ImThera Medical Inc. put to bed more than $1 million of a possible $2.2 million funding round that will go towards completing clinical trials of an implantable neurostimulation device for sleep apnea.
Officials at the San Diego, Calif.-based company described the financing as a “tranche in a larger $5 million B round,” which is expected to close sometime in December, according to ImThera CEO and founder Marcelo Lima.
Three companies — Abiomed Inc., Elixir Medical Inc. and ImThera Medical Inc. — are touting the results of clinical trials:
ImThera Medical, Inc. today announced interim results from its OSA European clinical study. For the study, ten patients have been surgically implanted with ImThera’s aura6000™ hypoglossal nerve neurostimulation device for treating Obstructive Sleep Apnea (OSA). The target population for ImThera’s neurostimulation device is moderate and severe OSA patients who are non-compliant with or cannot tolerate Continuous Positive Airway Pressure (CPAP).